Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.41 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.41 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.41 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.41 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.41 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.40 |
| ▸ | CTSD | P07339 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6136289 | 1.00 | LTA4H (0.55) | LTA4HHPGDEPHX1KMT2AEPHX2 | |
| SCHEMBL6136574 | 0.98 | LTA4H (0.52) | LTA4HHPGDEPHX1KMT2AEPHX2 | |
| SCHEMBL4414768 | 0.98 | LTA4H (0.52) | LTA4HHPGDEPHX1KMT2AEPHX2 | |
| SCHEMBL4424684 | 0.91 | SMN1; SMN2 (0.49) | LTA4HEPHX1SMN1; SMN2RAB9APOLB | |
| SCHEMBL6136421 | 0.91 | SMN1; SMN2 (0.49) | LTA4HEPHX1SMN1; SMN2RAB9APOLB | |
| SCHEMBL7437533 | 0.85 | HPGD (0.57) | LTA4HHPGDEPHX1KMT2AEPHX2 | |
| SCHEMBL11357838 | 0.83 | ALDH1A1 (0.53) | LTA4HHPGDEPHX1KMT2AEPHX2 | |
| SCHEMBL7882899 | 0.83 | KMT2A (0.53) | HPGDEPHX1KMT2AEPHX2SMN1; SMN2 | |
| SCHEMBL6138081 | 0.81 | HPGD (0.46) | LTA4HHPGDEPHX1KMT2AEPHX2 | |
| SCHEMBL6138080 | 0.81 | HPGD (0.46) | LTA4HHPGDEPHX1KMT2AEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0951464-B1 | N-(ARYL/HETEROARYLACETYL) AMINO ACID ESTERS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS | ELAN PHARM INC (US) | 2005-05-11 | — | — | EP | claimed |
| EP-1047391-A4 | ALPHA-AMIDES OF L-AMINO ACIDS AS FRAGRANCE PRECURSORS | GILLETTE CO (US) | 2005-01-19 | — | — | EP | claimed |
| US-6238655-B1 | USEFUL IN THE FORMULATION OF DEODORANTS, ANTIPERSPIRANTS, BODY SPRAYS, AND OTHER SKIN TREATMENT COMPOSITIONS. | THE GILLETTE COMPANY | 2001-05-29 | — | — | US | claimed |
| EP-1047391-A1 | ALPHA-AMIDES OF L-AMINO ACIDS AS FRAGRANCE PRECURSORS | THE GILLETTE COMPANY (US) | 2000-11-02 | — | — | EP | claimed |
| WO-1999030679-A1 | α-AMIDES OF L-AMINO ACIDS AS FRAGRANCE PRECURSORS | THE GILLETTE COMPANY (US) | 1999-06-24 | — | — | WO | claimed |
| US-6861558-B2 | Methods and compounds for inhibiting β-amyloid peptide release and/or its synthesis | ELAN PHARMACEUTICALS, INC. (US) | 2005-03-01 | — | — | US | disclosed |
| EP-1047391-A4 | ALPHA-AMIDES OF L-AMINO ACIDS AS FRAGRANCE PRECURSORS | GILLETTE CO (US) | 2005-01-19 | — | — | EP | disclosed |
| US-20040058900-A1 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | WU JING (US) | 2004-03-25 | — | — | US | disclosed |
| US-20040043977-A1 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | WU JING (US) | 2004-03-04 | — | — | US | disclosed |
| US-6683075-B1 | FUSED NITROGENHETEROCYCLIC AMIDES; ALZHEIMER'S DISEASE | ATHENA NEUROSCIENCES, INC. | 2004-01-27 | — | — | US | disclosed |
| US-6667305-B1 | Alzheimer's disease; beta-amyloid peptide is a small fragment of the amyloid precursor protein | ATHENA NEUROSCIENCES, INC. | 2003-12-23 | — | — | US | disclosed |
| US-6653303-B1 | Fused nitroheterocycle with amino and amido functionality; inhibiting beta-amyloid peptide release and/or synthesis; Alzheimer's disease | ATHENA NEUROSCIENCES, INC. | 2003-11-25 | — | — | US | disclosed |
| US-6635632-B1 | Alzheimer's disease | ATHENA NEUROSCIENCES, INC. | 2003-10-21 | — | — | US | disclosed |
| US-6559141-B2 | Inhibit beta-amyloid peptide release and/or synthesis, use in treating Alzheimer's disease; for example, 5-(N'-(phenylacetyl)-L-alpha-(2-thienyl)glycinyl)-amino-7-methyl-5,7-dihydro-6H-dibenz(b, d)azepin-6-one | ATHENA NEUROSCIENCES, INC. | 2003-05-06 | — | — | US | disclosed |
| US-6544978-B2 | Treating Alzheimer's disease both prophylactically and therapeutically | ATHENA NEUROSCIENCES, INC. | 2003-04-08 | — | — | US | disclosed |
| US-6506782-B1 | Compounds which inhibit beta -amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits beta | ATHENA NEUROSCIENCES, INC. | 2003-01-14 | — | — | US | disclosed |
| US-6476263-B1 | Compounds for inhibiting β-amyloid peptide release and/or its synthesis | ELAN PHARMACEUTICALS, INC. | 2002-11-05 | — | — | US | disclosed |
| US-6238655-B1 | USEFUL IN THE FORMULATION OF DEODORANTS, ANTIPERSPIRANTS, BODY SPRAYS, AND OTHER SKIN TREATMENT COMPOSITIONS. | THE GILLETTE COMPANY | 2001-05-29 | — | — | US | disclosed |
| EP-1047391-A1 | ALPHA-AMIDES OF L-AMINO ACIDS AS FRAGRANCE PRECURSORS | THE GILLETTE COMPANY (US) | 2000-11-02 | — | — | EP | disclosed |
| WO-1999030679-A1 | α-AMIDES OF L-AMINO ACIDS AS FRAGRANCE PRECURSORS | THE GILLETTE COMPANY (US) | 1999-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040043977-A1 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | BACE1, APP, BACE2 | LTA4H 147/4885HPGD 509/4885EPHX1 1482/4885 |
| US-20040058900-A1 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | BACE1, APP, BACE2 | LTA4H 147/4885HPGD 509/4885EPHX1 1482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.